Stock LPTX LEAP THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Real-time Estimate Cboe BZX
Other stock markets
 11:34:36 2024-04-29 am EDT 		5-day change 1st Jan Change
3.22 USD -0.92% Intraday chart for Leap Therapeutics, Inc. +1.56% -21.35%
Apr. 10 Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP CI
Mar. 19 Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating MT

Evolution of the average Target Price on Leap Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

25182655190b3848a601fefc9964.O_w58ZQ5hn7Jtv_7qVIBVch8ScW2D_RYLBEFrpLXM4I.XZR8s6BUqxz55s-S4z1VAa8kGrXTbJoIWFhu6dSWZbJiyQ-d4GzFM6_DmA~acff08d9c521eef36086acc8b92add9a

Analyst Recommendations on Leap Therapeutics, Inc.

Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating MT
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating MT
Baird Lowers Price Target on Leap Therapeutics to $20 From $30, Maintains Outperform Rating MT
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating MT
Raymond James Adjusts Price Target on Leap Therapeutics to $17 From $20, Keeps Outperform Rating MT
Raymond James Adjusts Price Target on Leap Therapeutics to $2 From $2.50, Maintains Outperform Rating MT
Mizuho Adjusts Price Target on Leap Therapeutics to $2 From $3, Maintains Buy Rating MT
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $3 From $6, Maintains Buy Rating MT
HC Wainwright Lowers Price Target on Leap Therapeutics to $2.50 From $4, Maintains Buy Rating MT
Raymond James Adjusts Price Target on Leap Therapeutics to $2.50 From $3.50, Maintains Outperform Rating MT
Raymond James Adjusts Leap Therapeutics' Price Target to $3 from $4, Keeps Outperform Rating MT
Piper Sandler Adjusts Leap Therapeutics' Price Target to $4 From $6, Reiterates Overweight Rating MT
Piper Sandler Adjusts Leap Therapeutics' Price Target to $6 From $5, Reiterates Overweight Rating MT
LEAP THERAPEUTICS : Mizuho Securities Starts Leap Therapeutics at Buy With $6 Price Target MT
LEAP THERAPEUTICS : Raymond James Lifts Leap Therapeutics' Price Target to $4 from $3, Keeps Outperform Rating MT
ANALYST RECOMMENDATIONS : American express, CrowdStrike, Five Below, J.M. Smucker, Lululemon... Our Logo
LEAP THERAPEUTICS : Baird Starts Leap Therapeutics at Outperform with $5 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.25 USD
Average target price
11.75 USD
Spread / Average Target
+261.54%
High Price Target
16 USD
Spread / Highest target
+392.31%
Low Price Target
7 USD
Spread / Lowest Target
+115.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Leap Therapeutics, Inc.

Baird
Mizuho Securities
Raymond James
HC Wainwright
Piper Sandler

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LPTX Stock
  4. Consensus Leap Therapeutics, Inc.